Citius Oncology (CTOR) Preferred Stock Liabilities (2022 - 2024)
Citius Oncology (CTOR) posted quarterly Preferred Stock Liabilities of $49.2 million for Q2 2024, down 29.16% year-over-year from $69.4 million in Q3 2023, and up 1.73% quarter-over-quarter from $48.3 million in Q1 2024.
Citius Oncology (CTOR) Preferred Stock Liabilities (2022 - 2024) Analysis & Trends
Citius Oncology (CTOR) has reported Preferred Stock Liabilities for 3 consecutive years, with $49.2 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Preferred Stock Liabilities fell 29.16% year-over-year to $49.2 million; the TTM figure through Jun 2024 stood at $49.2 million (down 29.16% YoY), while the FY2023 annual figure was $72.6 million, up 7.01% from the prior year.
- Preferred Stock Liabilities advanced to $49.2 million in Q2 2024 per CTOR's latest filing, from $48.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $72.6 million in Q4 2023 and bottomed at $48.3 million in Q1 2024.
- Historically, Preferred Stock Liabilities has averaged $63.8 million across 3 years, with a median of $68.6 million in 2023.
- Annual changes were most pronounced in 2023 — Preferred Stock Liabilities climbed 7.01% — and 2024, when it declined 29.54%.
- Citius Oncology's Preferred Stock Liabilities stood at $67.8 million in 2022, then climbed by 7.01% to $72.6 million in 2023, then tumbled by 32.26% to $49.2 million in 2024.
- Business Quant data shows CTOR's Preferred Stock Liabilities at $49.2 million in Q2 2024, $48.3 million in Q1 2024, and $72.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 49.15 Mn |
| Mar 31, 2024 | 48.32 Mn |
| Dec 31, 2023 | 72.57 Mn |
| Sep 30, 2023 | 70.63 Mn |
| Jun 30, 2023 | 69.39 Mn |
| Mar 31, 2023 | 68.57 Mn |
| Dec 31, 2022 | 67.81 Mn |